Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer

Review of current literature

M. Varma, B. Jasani

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Immunohistochemistry is widely used to distinguish prostate cancer from benign mimics and to establish the prostatic origin of poorly differentiated carcinoma. We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of α-methylacyl coenzyme A racemase (AMACR) in prostate cancer. The description of newer urothelial markers to aid the distinction of prostate cancer from urothelial carcinoma is also presented together with refinements in the quality control of PSA and PSAP immunostaining. Although AMACR is a useful immunohistochemical marker for prostate cancer, it has significant limitations. These limitations are discussed and the need for interpreting AMACR immunoreactivity in the appropriate morphological context and in conjunction with basal call markers is emphasized. We also describe the utility of an immunohistochemical panel composed of PSA, PSAP and high molecular weight cytokeratin for distinguishing poorly differentiated prostate cancer from high-grade urothelial carcinoma. A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalHistopathology
Volume47
Issue number1
DOIs
Publication statusPublished - Jul 2005
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Immunohistochemistry
Carcinoma
Racemases and Epimerases
Surgical Pathology
Coenzyme A
Keratins
Quality Control
Differential Diagnosis
Molecular Weight

Keywords

  • AMACR
  • High-molecular-weight cytokeratin
  • Immunohistochemistry
  • p63
  • Prostate

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer : Review of current literature. / Varma, M.; Jasani, B.

In: Histopathology, Vol. 47, No. 1, 07.2005, p. 1-16.

Research output: Contribution to journalArticle

@article{94101cdb62044406ad01eab466398953,
title = "Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: Review of current literature",
abstract = "Immunohistochemistry is widely used to distinguish prostate cancer from benign mimics and to establish the prostatic origin of poorly differentiated carcinoma. We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of α-methylacyl coenzyme A racemase (AMACR) in prostate cancer. The description of newer urothelial markers to aid the distinction of prostate cancer from urothelial carcinoma is also presented together with refinements in the quality control of PSA and PSAP immunostaining. Although AMACR is a useful immunohistochemical marker for prostate cancer, it has significant limitations. These limitations are discussed and the need for interpreting AMACR immunoreactivity in the appropriate morphological context and in conjunction with basal call markers is emphasized. We also describe the utility of an immunohistochemical panel composed of PSA, PSAP and high molecular weight cytokeratin for distinguishing poorly differentiated prostate cancer from high-grade urothelial carcinoma. A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice.",
keywords = "AMACR, High-molecular-weight cytokeratin, Immunohistochemistry, p63, Prostate",
author = "M. Varma and B. Jasani",
year = "2005",
month = "7",
doi = "10.1111/j.1365-2559.2005.02188.x",
language = "English",
volume = "47",
pages = "1--16",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley Blackwell",
number = "1",

}

TY - JOUR

T1 - Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer

T2 - Review of current literature

AU - Varma, M.

AU - Jasani, B.

PY - 2005/7

Y1 - 2005/7

N2 - Immunohistochemistry is widely used to distinguish prostate cancer from benign mimics and to establish the prostatic origin of poorly differentiated carcinoma. We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of α-methylacyl coenzyme A racemase (AMACR) in prostate cancer. The description of newer urothelial markers to aid the distinction of prostate cancer from urothelial carcinoma is also presented together with refinements in the quality control of PSA and PSAP immunostaining. Although AMACR is a useful immunohistochemical marker for prostate cancer, it has significant limitations. These limitations are discussed and the need for interpreting AMACR immunoreactivity in the appropriate morphological context and in conjunction with basal call markers is emphasized. We also describe the utility of an immunohistochemical panel composed of PSA, PSAP and high molecular weight cytokeratin for distinguishing poorly differentiated prostate cancer from high-grade urothelial carcinoma. A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice.

AB - Immunohistochemistry is widely used to distinguish prostate cancer from benign mimics and to establish the prostatic origin of poorly differentiated carcinoma. We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of α-methylacyl coenzyme A racemase (AMACR) in prostate cancer. The description of newer urothelial markers to aid the distinction of prostate cancer from urothelial carcinoma is also presented together with refinements in the quality control of PSA and PSAP immunostaining. Although AMACR is a useful immunohistochemical marker for prostate cancer, it has significant limitations. These limitations are discussed and the need for interpreting AMACR immunoreactivity in the appropriate morphological context and in conjunction with basal call markers is emphasized. We also describe the utility of an immunohistochemical panel composed of PSA, PSAP and high molecular weight cytokeratin for distinguishing poorly differentiated prostate cancer from high-grade urothelial carcinoma. A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice.

KW - AMACR

KW - High-molecular-weight cytokeratin

KW - Immunohistochemistry

KW - p63

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=22144496489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144496489&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2005.02188.x

DO - 10.1111/j.1365-2559.2005.02188.x

M3 - Article

VL - 47

SP - 1

EP - 16

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -